Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

NCT03307785 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03307785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03307785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 12, 2017
Completion date
December 11, 2024
Enrollment
60 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, neoplasms, non small cell lung cancer, non small cell lung cancer metastatic, non small cell lung cancer stage iiib, solid tumor